YARW
NASDAQ HealthcareYarrow Bioscience, Inc. - Common Stock
Biotechnology
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
๐ Market Data
| Price | $20.00 |
|---|---|
| Volume | 228,609 |
| Market Cap | 186.09M |
| Beta | 2.080 |
| RSI (14-Day) | 51.6 |
| 200-Day MA | $21.76 |
| 50-Day MA | $25.95 |
| 52-Week High | $46.95 |
| 52-Week Low | $16.05 |
| Forward P/E | -12.12 |
| Price / Book | -0.77 |
๐ฏ Investment Strategy Scores
YARW scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (92/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ Institutional Whale (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find YARW in your text
Paste any article, transcript, or post โ the tool will extract YARW and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-10-29.